We were delighted to participate in the Entrepreneurship Series 2026 organised by the Hong Kong Life Sciences Society (HKLSS), where our Principal, Pauli Wong, delivered a session on "Patent Strategy for Life Sciences Spinouts: From Discovery to Deal-Ready IP". Pauli shared practical insights into the various forms of IP and patent protection available to innovators, key considerations for safeguarding life sciences inventions, and the unique IP opportunities and challenges facing businesses operating across the Greater Bay Area (GBA).

Thank you to HKLSS for the invitation and to all attendees for the engaging discussion. Eagle IP remains committed to supporting innovation, entrepreneurship, and the growth of Hong Kong's life sciences ecosystem.

我們過去活動

Jennifer Che and Pauli Wong Co-Teach Advanced Patent Skills Seminar at HKU-TEC

2026年10月15日

BioHK2026 | Biotech IP in practice

2026年9月16日

Jennifer Che Once Again Named to the IAM Strategy 300

2026年8月21日

Yolanda Wang attended the 1st China Pharmaceutical Innovation Conference

2026年7月22日

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

2026年6月16日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

2026年6月5日

Recommended Insights

The Secret Prior Art Trap: A Case Study on Conflicting Applications in China

2025年11月13日
In patent prosecution, the concept of a "conflicting application" or “secret prior art” plays a critical role in determining the patentability of an invention. This article explores the framework for assessing conflicting applications under Chinese patent law, with a comparative perspective on the approaches adopted in the United States. Case Background: The Image Encoding Dispute […]
閱讀更多 >

Do Invention and UM Patents Filed on the Same Day Rise and Fall Together?

2021年8月19日
Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Seminal Cases by the SPC Recently, the Intellectual Property Division of the Supreme People's Court (SPC) issued a list of seminal (精品) cases. Although China is not a case law country, such seminal cases issued by the SPC have high guiding impact for […]
閱讀更多 >

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

2025年4月1日
“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]
閱讀更多 >

China’s Newest Examination Guidelines: Post-Filing Supplemental Data for Compounds (Part I)

2021年4月28日
Post-filing data in China has been a constant issue for many patent practitioners around the world. Examiners seem to require it often, and yet the rules regarding when it is acceptable have seemed much stricter than other jurisdictions worldwide. In fact, we tried to summarize the latest state of the law in an earlier blog […]
閱讀更多 >
Top crossarrow-right